Chronic myelogenous leukemia

Susan O'Brien*, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations

Abstract

CML is a hematopoietic stem cell disease characterized by the presence of Ph chromosome resulting from the translocation between chromosomes 9 and 22 [t(9;22)].

Original languageEnglish (US)
Pages (from-to)984-1023
Number of pages40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number9
DOIs
StatePublished - Oct 2009

Keywords

  • Allogenic HSCT
  • Chronic myelogenous leukemia
  • Cytogenetic response
  • Dasatinib
  • Hematologic response
  • Imatinib
  • Karyotyping
  • NCCN Clinical Practice Guidelines
  • Nilotinib
  • Transplantation

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this